WE CARE FOR EXCELLENT EXPERTISE
Experienced Supervisory Board Members with a Wide Range of Expertise
The Curetis supervisory board also brings together outstanding specialist expertise in the fields of in-vitro diagnostics, life sciences and venture capital, and supports Curetis in its activities across the entire value-chain.
William E. Rhodes III - Chairman of the Supervisory Board
William E. Rhodes, III, has been appointed as the chairman of the Supervisory Board. Mr. Rhodes is a healthcare executive with more than 30 years of experience in the healthcare industry. During his 14-year career at Becton, Dickinson and Company (BD, 1998-2012) Mr. Rhodes served several senior leadership positions, including such roles as Worldwide President of BD Biosciences (2009-2011), a greater than US$ 1 billion revenue segment of BD. He was also an Executive Officer of BD, and was responsible for corporate strategy and merger and acquisition funcitions for all of BD's businesses. Furthermore, he founded BD Ventures, the venture capital arm of Becton, Dickinson and Co. Prior to Becton Dickinson, he served in senior business development positions at Johnson & Johnson and Pfizer Inc. Mr. Rhodes also served as president at The William-James Co. and has a track record of over 20 successful acquisitions and divestitures. He was director of Andor Technologies plc (2013-2014), and has served on the boards of Novocell Inc., Conticare Medical, Vitagen Inc., the California Healthcare Institute, BIO, San Jose State University Research Foundation and Silicon Valley Leadership Group. He currently serves as director of Third Day Advisors LLC (since 2013), as director of Omega Group plc (since 2013), Paramit Corporation LLC (since 2014) and Cellector Corporation (since 2015), and as a member of the Advisory Board of Cayuga Venture Fund (since 2013). Mr. Rhodes has a number of advisory roles with Cornell University, including serving on the Advisory Councils of Mc Govern Family Center of Life Sciences (since 2013) and Entrepreneurship at Cornell (since 2015). He also was appointed to the Cornell College of Agriculture and Life Sciences Dean's Council (2016) and serves as a Venture Consultant for Cornell's Blackstone Launchpad (2016). Moreover, he is on the Editorial Board of the journal Clinical and Translational Medicine. Mr. Rhodes holds a Masters degree in International Business from Seton Hall University and a BSc degree from Cornell University. He originated eleven US patents for novel topical drugs and has been a lecturer on entrepreneurship in life sciences, innovation technology and M&A at Cornell University, Seton Hall University and San Jose State University.
Mario Crovetto - Chairman of the Audit Committee
Mario Crovetto has been appointed as the chairman of the Audit Committee. Mr. Crovetto currently works as an independent advisor on M&A and corporate projects, notably integrations, divestments and financing since 2011. From 1999 to 2011 he was the CFO of Eurand NV (Specialty Pharmaceuticals), which he took public to NASDAQ in 2007. In the 1990 to 1999 period he held various senior business positions at Recordati (Pharmaceuticals) including VP of Corporate Development, Division Manager of Diagnostics and CFO. Prior to that he held various positions at Montedison (Speciality Chemicals), Digital Equipment Corporation, Mobil and SIAR (Management Consulting). Mr. Crovetto holds a BSc in Economics from the Università Cattolica del Sacro Cuore, Milan and a master's degree in Business Economics of Harvard University, Cambridge, MA.
DR. WERNER SCHÄFER - Vice-Chairman
Dr. Werner Schäfer is an experienced specialist in the in-vitro diagnostics industry and has held various international management positions throughout his career, at Behringwerke/Hoechst, Abbott, Boehringer Mannheim and Roche, for example. At Roche, he headed up the laboratory systems business unit and was also a member of the executive board at Roche Diagnostics GmbH until 2002. Since then, he has worked as a consultant and serves on various executive boards and supervisory boards in highly specialized diagnostics and medical technology companies. Dr. Schäfer was also a member of the supervisory boards during the M&A phase in companies such as BRAHMS (sold to Thermo Fischer), mtm Laboratories (sold to Roche) and Vivacta (sold to Novartis). All of these companies achieved a very successful exit for their shareholders and partners. He currently serves as Chairman of the Board of Directors at ProteoMediX AG and on the supervisory boards of Human, Genomatix and ProteoMediX AG.
Prabhavathi Fernandes, Ph.D. - Member of the Board
Dr. Prabhavathi Fernandes has been appointed member of the Supervisory Board. Until her retirement in December 2016, she was President and Chief Executive Officer and a Member of the Board of Directors of Cempra Pharmaceuticals, a company she has founded. In 2012, she led the initial public offering and listing on Nasdaq for Cempra, and has successfully raised over half a billion dollars to date for the company. Her career of more than four decades has focused on anti-infectives, first in clinical microbiology and infectious diseases and then in pharmaceutical discovery and development. Prior to Cempra, Dr. Fernandes held executive leadership positions at pharmaceutical corporations including Bristol-Myers Squibb Pharmaceutical Research Institute, Abbott Laboratories and The Squibb Institute for Medical Research. She founded and led three biotechnology and CRO companies. She serves on the editorial board of several journals and she has authored over 250 publications and numerous reviews and book chapters.
Dr. Rudy Dekeyser - Member of the Board
Rudy Dekeyser, PhD, joined LSP in 2012. He became a Partner of the firm in that same year. Rudy’s prime focus and responsibility within LSP is to invest in unlisted securities. Prior to joining LSP, Rudy was Managing Director of VIB, the Flanders Institute for Biotechnology, which he helped establish in 1995. Under his leadership, the Institute has grown to become one of Europe’s most successful incubators in the area of life sciences. From within the Institute, several top quality companies were established and numerous business development deals were struck with large industry players. Rudy brings company building skills to the LSP team. Over the years, Rudy has been appointed a Director of many companies and has been a senior Advisor to a number of investment firms. In addition, he currently chairs the Technology Transfer Board of the prestigious European molecular biology research institute EMBL in Heidelberg, Germany. Rudy also chairs the Valorisation Board of the Dutch Genomics Initiative (NGI), assembling top researchers from sixteen research centres in The Netherlands responsible for breakthroughs in the fields of health, agriculture and food. Rudy has a Master’s degree in zoology and a PhD in molecular biology from the University of Gent.
DR. HOLGER REITHINGER - Member of the Board
Dr. Holger Reithinger has been a General Partner and Head of the Munich office of Forbion Capital Partners since April 2010. Previously, he was Principal and subsequently Partner at Global Life Science Ventures, a well-established life sciences-focused partnership with offices in Switzerland and Germany. He started his career in venture capital in 1997 as an Investment Manager at Technologieholding VC GmbH, which at that time was one of the leading German venture capital firms. Technologieholding was acquired by 3i Group in early 2000, when Dr. Reithinger became a Director at its Germany's healthcare practice. Prior to this, Dr. Reithinger gained operational experience as a Product Development Manager at Biometra/Whatman Plc (now part of GE Healthcare). Dr. Reithinger has served on the boards of numerous life sciences companies including Epigenomics (IPO 2004), MBT (assets sold to Medigene AG), 4SC (IPO 2005), Fibrex Medical (assets licensed to Ikaria Inc.), Agendia BV, Santaris A/S (sold to Roche 2014) and Cellnovo Limited (2014-2015). Dr. Reithinger currently holds board seats at Curetis (since 2011), Cellnovo Group S.A. (since 2015, IPO 2015), Allecra Therapeutics GmbH (since 2013), Rigontec GmbH (since 2015) and catalYm GmbH (since 2016). Dr. Reithinger studied Molecular Biology/Microbial Biology and Biochemistry at the Universities of Heidelberg and Munich. He holds a PhD in Biochemistry, which he obtained under the supervision of Prof. Dr. Arne Skerra (founder of Forbion's portfolio company Pieris AG) in the department of Prof. Dr. Hartmut Michel (Nobel Laureate 1988) at the Max-Planck-Institute of Biophysics.